Skip to content

Platelet-rich Plasma Injections for Persistent Medial Knee Pain After Total Knee Arthroplasty

Efficacy of Platelet-rich Plasma Injections for the Treatment of Persistent Medial Knee Pain After Total Knee Arthroplasty

Status
Withdrawn
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03225092
Enrollment
0
Registered
2017-07-21
Start date
2017-07-18
Completion date
2019-06-30
Last updated
2020-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Pain Chronic, Pes Anserinus Bursitis, Status-Post Total Knee Arthroplasty

Keywords

Chronic Knee Pain, Status-Post Total Knee Arthroplasty, Platelet Rich Plasma

Brief summary

This study will investigate the potential effects of platelet rich plasma for the treatment of persistent medial knee pain after total knee arthroplasty. All study participants will receive PRP injections and will be followed up to see if any benefit in regards to pain and/or function is achieved.

Detailed description

This study aims to investigate the efficacy of platelet-rich plasma (PRP) injections for the treatment of persistent medial knee pain after total knee arthroplasty (TKA). The investigators hypothesize that PRP injections will provide meaningful pain relief and improved functionality for patients suffering from post-TKA residual pain. The incidence of residual pain after TKA ranges between 10-34%. Many of these patients can be effectively managed by physical therapy, orthotics, and pes anserine bursa corticosteroid injections. However, there remain a number of refractory cases that are frustrating for both the patient and physician. With the advent of interventional pain management, advanced interventions for this clinical problem have focused on selective nerve blocks and ablations targeting the infrapatellar branch of the saphenous nerve. More recently, attention has been paid to the role of patient biology and inflammatory mediators in the development of post-arthroplasty pain (including IL-6 and CRP). If individual patient biology is the foundation of post-TKA pain, then biologic interventions aimed at restoring the balance of these mediators (such as PRP), rather than ablative procedures, seems preferable. Furthermore, while intra-operative PRP has been studied for its effects on wound healing, blood loss, and post-operative pain control, no study has investigated its utility in treating residual medial knee pain after TKA. All injections will be performed by the same board-certified sports medicine and musculoskeletal ultrasound physician. There will be no activity restrictions following the procedure. Descriptive statistics will be used to report mean changes in outcome scores. Data will be analyzed with a 2-sample t-test.

Interventions

BIOLOGICALUltrasound-guided platelet rich plasma injection

Each participant will receive a single injection into the pes anserine bursa (using the Arthrex Angel system with a setting of 180cc of peripheral blood and 1% hematocrit concentration) under sterile technique

Sponsors

Ohio State University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Observational pilot study

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Person has had a total knee arthroplasty (total knee replacement) 2. Has experienced persistent medial knee pain beyond six months after surgery 3. Has the presumed diagnosis of pes anserine bursitis 4. No pain relief with conventional treatments such as arch supports (if one is flatfooted), NSAID's, and at least two local steroid injections

Exclusion criteria

1. Person has had a prior knee surgical procedure other than the total knee arthroplasty or an arthroscopic debridement procedure 2. Evidence of knee instability, prosthetic loosening, knee infection, radiculopathy, or hip or back pain 3. Personal history of chronic narcotic or recreational drug use, smoking, psychiatric disorders, or a total hip arthroplasty on the same side of the knee arthroplasty 4. Body mass index (BMI) of greater than 35

Design outcomes

Primary

MeasureTime frameDescription
Knee Society ScoreChange from baseline to 6 months is primary outcome. Additional outcomes will be collected at 1 and 3 months after procedure.Knee Society Scores, a score measurement created by The Knee Society, will be collected as below.

Secondary

MeasureTime frameDescription
The Hospital for Special Surgery (HSS) Knee ScoreRecorded as a baseline and then at 1, 3, and 6 months post interventionKnee Scores, a score measurement created by The Hospital for Special Surgery, will be collected as below.
Visual Analog Scale (VAS) for PainRecorded as a baseline and then at 1, 3, and 6 months post interventionA patient-reported measurement where the subjects will rate their knee pain level by placing a mark along a 100 millimeter line (with each millimeter corresponding to a number, from 0 to 100, 0 meaning no pain at all and 100 meaning the worst pain possible).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026